Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the relative efficacy and toxicity of combination
therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising
PSA.
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System